Cargando…
Identification of women with early breast cancer by analysis of p43-positive lymphocytes
Regular screening mammographies and increasing knowledge of high-risk groups have resulted in an improvement in the rate of detection of smaller malignant lesions. However, uncertain minimal mammographic features frequently require further costly and often uncomfortable investigation, including repe...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362289/ https://www.ncbi.nlm.nih.gov/pubmed/10360668 http://dx.doi.org/10.1038/sj.bjc.6690434 |
_version_ | 1782153420824641536 |
---|---|
author | Auerbach, L Hellan, M Stierer, M Rosen, A C Ausch, C Obwegeser, R Kubista, E Wolf, G Rosen, H R |
author_facet | Auerbach, L Hellan, M Stierer, M Rosen, A C Ausch, C Obwegeser, R Kubista, E Wolf, G Rosen, H R |
author_sort | Auerbach, L |
collection | PubMed |
description | Regular screening mammographies and increasing knowledge of high-risk groups have resulted in an improvement in the rate of detection of smaller malignant lesions. However, uncertain minimal mammographic features frequently require further costly and often uncomfortable investigation, including repeat radiological controls or surgical procedures, before cancerous lesions can be identified. Placental isoferritin (p43), a protein with immunosuppressive effects, has been detected on the surface of lymphocytes taken from peripheral blood in patients with breast cancer. In this study we evaluated the sensitivity and specificity of the expression of p43-positive lymphocytes as a marker in early stage breast cancer and also investigated its expression on T-cell subpopulations. The presence of p43-positive lymphocytes was investigated using the monoclonal antibody CM-H-9 and flow cytometry in 76 women with controversial, non-palpable mammographic findings who were undergoing surgical biopsy. Patients with early breast cancer (n = 48) had significantly higher p43-positive cell values (median 3.83%, range 0.98–19.4) than patients with benign lumps (n = 28, median 1.43%, range 0.17–3.7) or controls (n = 22, median 1.3%, range 0.4–1.87) (P < 0.0001). At a cut-off level of 2% p43-positive cells a sensitivity of 91.7% and a specificity of 89.3% for detection of breast cancer could be reached. While the median ratio of total CD4+/CD8+ cells was 2.6, a ratio of 1.3 was found for the p43-positive subpopulation (P < 0.001), thus indicating a significant link between p43 and CD8+ cells. The determination of p43-positive lymphocytes in peripheral blood could serve as an additional diagnostic tool in patients with controversial mammographic findings and could also reduce the need for cost-intensive and often uncomfortable management of these patients. © 1999 Cancer Research Campaign |
format | Text |
id | pubmed-2362289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23622892009-09-10 Identification of women with early breast cancer by analysis of p43-positive lymphocytes Auerbach, L Hellan, M Stierer, M Rosen, A C Ausch, C Obwegeser, R Kubista, E Wolf, G Rosen, H R Br J Cancer Regular Article Regular screening mammographies and increasing knowledge of high-risk groups have resulted in an improvement in the rate of detection of smaller malignant lesions. However, uncertain minimal mammographic features frequently require further costly and often uncomfortable investigation, including repeat radiological controls or surgical procedures, before cancerous lesions can be identified. Placental isoferritin (p43), a protein with immunosuppressive effects, has been detected on the surface of lymphocytes taken from peripheral blood in patients with breast cancer. In this study we evaluated the sensitivity and specificity of the expression of p43-positive lymphocytes as a marker in early stage breast cancer and also investigated its expression on T-cell subpopulations. The presence of p43-positive lymphocytes was investigated using the monoclonal antibody CM-H-9 and flow cytometry in 76 women with controversial, non-palpable mammographic findings who were undergoing surgical biopsy. Patients with early breast cancer (n = 48) had significantly higher p43-positive cell values (median 3.83%, range 0.98–19.4) than patients with benign lumps (n = 28, median 1.43%, range 0.17–3.7) or controls (n = 22, median 1.3%, range 0.4–1.87) (P < 0.0001). At a cut-off level of 2% p43-positive cells a sensitivity of 91.7% and a specificity of 89.3% for detection of breast cancer could be reached. While the median ratio of total CD4+/CD8+ cells was 2.6, a ratio of 1.3 was found for the p43-positive subpopulation (P < 0.001), thus indicating a significant link between p43 and CD8+ cells. The determination of p43-positive lymphocytes in peripheral blood could serve as an additional diagnostic tool in patients with controversial mammographic findings and could also reduce the need for cost-intensive and often uncomfortable management of these patients. © 1999 Cancer Research Campaign Nature Publishing Group 1999-05 /pmc/articles/PMC2362289/ /pubmed/10360668 http://dx.doi.org/10.1038/sj.bjc.6690434 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Auerbach, L Hellan, M Stierer, M Rosen, A C Ausch, C Obwegeser, R Kubista, E Wolf, G Rosen, H R Identification of women with early breast cancer by analysis of p43-positive lymphocytes |
title | Identification of women with early breast cancer by analysis of p43-positive lymphocytes |
title_full | Identification of women with early breast cancer by analysis of p43-positive lymphocytes |
title_fullStr | Identification of women with early breast cancer by analysis of p43-positive lymphocytes |
title_full_unstemmed | Identification of women with early breast cancer by analysis of p43-positive lymphocytes |
title_short | Identification of women with early breast cancer by analysis of p43-positive lymphocytes |
title_sort | identification of women with early breast cancer by analysis of p43-positive lymphocytes |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362289/ https://www.ncbi.nlm.nih.gov/pubmed/10360668 http://dx.doi.org/10.1038/sj.bjc.6690434 |
work_keys_str_mv | AT auerbachl identificationofwomenwithearlybreastcancerbyanalysisofp43positivelymphocytes AT hellanm identificationofwomenwithearlybreastcancerbyanalysisofp43positivelymphocytes AT stiererm identificationofwomenwithearlybreastcancerbyanalysisofp43positivelymphocytes AT rosenac identificationofwomenwithearlybreastcancerbyanalysisofp43positivelymphocytes AT auschc identificationofwomenwithearlybreastcancerbyanalysisofp43positivelymphocytes AT obwegeserr identificationofwomenwithearlybreastcancerbyanalysisofp43positivelymphocytes AT kubistae identificationofwomenwithearlybreastcancerbyanalysisofp43positivelymphocytes AT wolfg identificationofwomenwithearlybreastcancerbyanalysisofp43positivelymphocytes AT rosenhr identificationofwomenwithearlybreastcancerbyanalysisofp43positivelymphocytes |